Since there is no known functional impact of RBM10 on EGFR-mutant lung cancer treatment, we tested the hypothesis that RBM10 inactivation may modulate EGFR TKI sensitivity in EGFR-mutant LA. The gene discussed is EGFR; the disease is lung cancer.